Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis clinical trial (NCT06453317). Contact the study team or your healthcare provider for specific answers.

Question 2

How does the combination therapy compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis clinical trial (NCT06453317). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of the treatments being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis clinical trial (NCT06453317). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to visit the clinic for assessments and treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis clinical trial (NCT06453317). Contact the study team or your healthcare provider for specific answers.

Question 5

What should I expect during the trial in terms of medication administration and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis clinical trial (NCT06453317). Contact the study team or your healthcare provider for specific answers.

Question 6

How will this trial impact my overall treatment plan for ulcerative colitis?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis clinical trial (NCT06453317). Contact the study team or your healthcare provider for specific answers.

What this study is about